{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"2.7","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) and the sum must also demonstrate an absolute increase of at least 5mm, or unequivocal progression of existing non-target lesions, or the appearance of new lesions. Estimated using the Kaplan-Meier method.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nafatinib dimaleate: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Afatinib)"}],"paramType":"MEDIAN","populationDescription":"Analysis population includes patients from the main Phase II study","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Median Progression-free Survival (PFS ) Time","type":"SECONDARY","unitOfMeasure":"months"}